Systematic Functional Annotation of Somatic Mutations in Cancer
- PMID: 29533785
- PMCID: PMC5926201
- DOI: 10.1016/j.ccell.2018.01.021
Systematic Functional Annotation of Somatic Mutations in Cancer
Abstract
The functional impact of the vast majority of cancer somatic mutations remains unknown, representing a critical knowledge gap for implementing precision oncology. Here, we report the development of a moderate-throughput functional genomic platform consisting of efficient mutant generation, sensitive viability assays using two growth factor-dependent cell models, and functional proteomic profiling of signaling effects for select aberrations. We apply the platform to annotate >1,000 genomic aberrations, including gene amplifications, point mutations, indels, and gene fusions, potentially doubling the number of driver mutations characterized in clinically actionable genes. Further, the platform is sufficiently sensitive to identify weak drivers. Our data are accessible through a user-friendly, public data portal. Our study will facilitate biomarker discovery, prediction algorithm improvement, and drug development.
Keywords: TCGA; cellular assay; clinical marker; driver mutation; drug sensitivity; functional genomics; functional proteomics; therapeutic target.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures






Similar articles
-
On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Mol Cancer Ther. 2015 Jun;14(6):1488-94. doi: 10.1158/1535-7163.MCT-14-1061. Epub 2015 Apr 7. Mol Cancer Ther. 2015. PMID: 25852059
-
Knowledge base toward understanding actionable alterations and realizing precision oncology.Int J Clin Oncol. 2019 Feb;24(2):123-130. doi: 10.1007/s10147-018-1378-0. Epub 2018 Dec 12. Int J Clin Oncol. 2019. PMID: 30542800 Free PMC article. Review.
-
Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.Scand J Clin Lab Invest Suppl. 2016;245:S84-91. doi: 10.1080/00365513.2016.1210331. Epub 2016 Aug 17. Scand J Clin Lab Invest Suppl. 2016. PMID: 27542004
-
Genomic profiling in oncology clinical practice.Clin Transl Oncol. 2020 Sep;22(9):1430-1439. doi: 10.1007/s12094-020-02296-9. Epub 2020 Jan 24. Clin Transl Oncol. 2020. PMID: 31981077 Review.
-
Data resources for the identification and interpretation of actionable mutations by clinicians.Ann Oncol. 2017 May 1;28(5):946-957. doi: 10.1093/annonc/mdx023. Ann Oncol. 2017. PMID: 28327901 Review.
Cited by
-
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.J Thorac Oncol. 2020 Oct;15(10):1611-1623. doi: 10.1016/j.jtho.2020.05.021. Epub 2020 Jun 13. J Thorac Oncol. 2020. PMID: 32540409 Free PMC article.
-
Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers.JCO Precis Oncol. 2020 Sep 16;4:PO.19.00322. doi: 10.1200/PO.19.00322. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33015523 Free PMC article. No abstract available.
-
PIK3R1, HRAS and AR Gene Alterations Associated with Sclerosing Polycystic Adenoma of the Parotid Gland.Curr Issues Mol Biol. 2023 Jan 19;45(2):954-962. doi: 10.3390/cimb45020061. Curr Issues Mol Biol. 2023. PMID: 36826006 Free PMC article.
-
RBL1/p107 Expression Levels Are Modulated by Multiple Signaling Pathways.Cancers (Basel). 2021 Oct 8;13(19):5025. doi: 10.3390/cancers13195025. Cancers (Basel). 2021. PMID: 34638509 Free PMC article.
-
Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.Int J Mol Sci. 2023 Jul 23;24(14):11834. doi: 10.3390/ijms241411834. Int J Mol Sci. 2023. PMID: 37511593 Free PMC article.
References
-
- Bustamante CD, Townsend JP, Hartl DL. Solvent accessibility and purifying selection within proteins of Escherichia coli and Salmonella enterica. Molecular biology and evolution. 2000;17:301–308. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA016672/CA/NCI NIH HHS/United States
- U54 HG008100/HG/NHGRI NIH HHS/United States
- U24 CA210950/CA/NCI NIH HHS/United States
- P50 CA098258/CA/NCI NIH HHS/United States
- U01 CA168394/CA/NCI NIH HHS/United States
- U01 CA217842/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- F31 CA200266/CA/NCI NIH HHS/United States
- P50 CA070907/CA/NCI NIH HHS/United States
- R01 CA175486/CA/NCI NIH HHS/United States
- U01 CA176284/CA/NCI NIH HHS/United States
- U24 CA143883/CA/NCI NIH HHS/United States
- U24 CA209851/CA/NCI NIH HHS/United States
- R50 CA221675/CA/NCI NIH HHS/United States
- U24 CA204817/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous